一品红药业股份有限公司 关于独立董事独立性自查情况的专项报告 本人杨德明作为一品红药业股份有限公司的独立董事，在 2023 年度任职期 间恪尽职守，忠实履职，勤勉尽责，符合《上市公司独立董事管理办法》规定的 独立性要求，根据法律法规及相关规则的要求，现将本人 2023 年度独立性自查 情况报告如下： 1、本人及本人直系亲属、主要社会关系均不在该公司及其附属企业任职。 是□否 如否，请详细说明： 2、本人及本人直系亲属不是直接或间接持有该公司已发行股份 1%以上的股 东，也不是该上市公司前十名股东中自然人股东。 是□否 如否，请详细说明： 3、本人及本人直系亲属不在直接或间接持有该公司已发行股份 5%以上的股 东任职，也不在该上市公司前五名股东任职。 是□否 如否，请详细说明： 4、本人及本人直系亲属不在该公司控股股东、实际控制人的附属企业任职。 是□否 如否，请详细说明： 5、本人不是为该公司及其控股股东、实际控制人或者其各自的附属企业提 供财务、法律、咨询、保荐等服务的人员，包括但不限于提供服务的中介机构的 项目组全体人员、各级复核人员、在报告上签字的人员、合伙人、董事、高级管 理人员及主要负责人。 是□否 ...

证券代码：300723 证券简称：一品红 公告编号：2024-016 一品红药业股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 鉴于公司目前处于快速发展阶段，需要加大经营投入，为企业可持续发展奠 定坚实基础；同时，兼顾股东尤其是中小投资者利益需求，依据《公司法》及《公 司章程》的相关规定，董事会提议公司 2023 年度利润分配预案如下：以权益分 派股权登记日的总股本为基数（通过集中竞价交易方式回购的股份不参与利润分 配），每 10 股派发现金红利 2.1 元（含税），不送红股，不进行资本公积金转增 股本。经上述分配后，剩余未分配利润全部结转以后年度。 一品红药业股份有限公司（以下简称"公司"）2023 年度利润分配预案： 每 10 股派发现金 2.1 元（含税）； 本次利润分配方案实施时，如享有利润分配权的股本总额发生变动，则 以实施分配方案股权登记日时享有利润分配权的股本总额为基数，按照 每股分配金额不变的原则对分红总额进行调整。 本次利润分配预案尚待本公司2023年度股东大会审议通过后方 ...

二、出席会议情况 一品红药业股份有限公司 独立董事 2023 年度述职报告 （杨德明） 尊敬的各位股东及股东代表： 本人作为一品红药业股份有限公司（以下简称"公司"）第三届董事会的独 立董事，严格按照《公司法》、《上市公司独立董事管理办法》、《上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等有关法律法规、规范性法律文件 以及《公司章程》、《独立董事工作制度》等公司相关的规定和要求，忠实履行独 立董事的职责，勤勉尽责，积极出席公司相关会议，认真审议董事会各项议案， 审慎决策，对公司重大事项发表相关意见，充分发挥独立董事的独立性和专业性 作用，及时了解公司的生产经营信息，全面关注公司的发展状况，促进公司规范 运作，切实维护公司和全体股东特别是中小股东的合法权益。现将本人 2023 年 度履行独立董事职责的情况汇报如下： 一、独立董事基本情况 本人杨德明，男，中国国籍，无境外永久居留权，1975 年出生，博士学历， 现任暨南大学教授、博士生导师，兼任一品红药业股份有限公司、广东三和管桩 股份有限公司、广东开平农村商业银行股份有限公司独立董事（非上市公司）和 广东芳源环保股份有限公司独立董事。 2023 ...

Innovation and Manufacturing - The company has established two innovative bases: Yipinhong Lianrui Biopharmaceutical Intelligent Manufacturing Base and Yipinhong Pharmaceutical Production Base, enhancing flexible manufacturing capabilities[1] - The Yipinhong Lianrui Biopharmaceutical Intelligent Manufacturing Base was recognized as a "2023 Excellent Intelligent Manufacturing Scenario" by the Ministry of Industry and Information Technology, indicating its leading position in the pharmaceutical industry[1] - The Yipinhong Pharmaceutical Production Base was awarded the "Specialized, Refined, Characteristic, and Innovative Small and Medium-sized Enterprises" honor by the Guangdong Provincial Department of Industry and Information Technology[1] - The Yipinhong Pharmaceutical Production Base was recognized as a "National Green Factory" by the Ministry of Industry and Information Technology in January 2024[1] - The establishment of the two bases is expected to optimize product costs and improve market competitiveness through advanced intelligent manufacturing[1] - The company has completed the construction of the first phase of the Lianrui Intelligent Manufacturing Base, covering an area of 220,000 square meters, meeting GMP, FDA, and EU certification standards[83] Financial Performance - The company's operating revenue for 2023 was ¥2,503,447,004.47, representing a 9.79% increase from ¥2,280,198,601.88 in 2022[33] - The net profit attributable to shareholders for 2023 was ¥184,613,302.81, a decrease of 36.49% compared to ¥290,682,890.45 in 2022[33] - The net profit after deducting non-recurring gains and losses was ¥119,978,271.81, down 45.73% from ¥221,085,506.82 in the previous year[33] - The total assets at the end of 2023 amounted to ¥4,405,295,590.95, an increase of 7.49% from ¥4,098,442,245.37 at the end of 2022[33] - The net assets attributable to shareholders increased by 22.96% to ¥2,522,087,479.40 from ¥2,051,210,485.31 in 2022[33] - The basic earnings per share for 2023 was ¥0.420, a decrease of 37.96% from ¥0.677 in 2022[33] Research and Development - The company is focusing on enhancing its R&D capabilities through various innovative mechanisms, including independent and collaborative research[44] - The company has 10 registered raw material drug filing numbers and 17 raw material drug projects under research[84] - The company is advancing the Ruishi Innovative Raw Material Drug Project, which is expected to be ready for production by 2024[84] - The company has established a chronic disease research and development innovation center, with 38 projects in the pipeline, including the global innovative drug AR882[134] - The company has 7 vaccine projects in its research pipeline, leveraging a new gene-engineered vaccine development platform[130] - The company has established a comprehensive national market network, having developed over 19,000 terminal medical institutions in 2023[107] Product Development and Market Strategy - The company is committed to enhancing its R&D capabilities and expanding its product offerings in response to the evolving healthcare landscape and regulatory support for the pharmaceutical industry[98] - The company has received 15 new registration approvals in 2023, with a total of 10 registered active pharmaceutical ingredients and 17 projects under research[107] - The company’s innovative drug AR882 for hyperuricemia and gout has completed global multi-center Phase II clinical trials, with FDA approval for the Phase III clinical trial design, which has now been initiated[103] - The company has developed several advanced drug delivery technologies, including pediatric drug masking and precise dosing technologies, enhancing its product offerings[116] - The company has introduced new products including the oral drops of Levocetirizine and the oral solution of Carbocisteine, with three new pediatric drug registrations approved during the reporting period[137] Market Performance and Sales - Revenue from pharmaceutical manufacturing was ¥2,484,115,284.3, accounting for 99.23% of total revenue, with a year-on-year growth of 11.94%[62] - Revenue from children's medicines increased by 17.01% to ¥1,535,950,304.5, making up 61.35% of total revenue[62] - The Central China region saw a significant revenue increase of 67.93%, reaching ¥351,941,182.27[62] - The company’s sales volume increased by 56.02% to 94,505,174 boxes in 2023 compared to 60,571,356 boxes in 2022[70] - The company’s collective procurement products experienced a remarkable growth of 244.34%[70] Strategic Partnerships and Financing - The company secured a strategic cooperation with Agricultural Bank of China Guangzhou Branch, which will provide a credit line of 5 billion yuan to support global innovative drug research and development, technology innovation, and clinical trials[3] - The strategic cooperation with Agricultural Bank of China is expected to broaden the company's diversified financing channels and enhance financial flexibility[3] Corporate Social Responsibility and Recognition - The company has been recognized for its social responsibility efforts, including donations for disaster relief and support for children's health initiatives[88] - The company's stock has been included in margin trading and the ChiNext 200 index, indicating market recognition of its growth potential and investment value[88] - The company has received recognition for its strong research and development capabilities, receiving various honors in the pharmaceutical industry[132] Challenges and Future Outlook - The company reported a significant increase in direct material costs, which rose by 64.70% to ¥304,946,614.43, accounting for 64.26% of operating costs[34] - The chronic disease medication market is expected to continue growing, driven by an aging population and increasing healthcare demands, with 29,697 million people aged 60 and above in China as of the end of 2023[102] - The pharmaceutical manufacturing industry in China is expected to see a revenue growth of 5% in 2024, with the terminal market sales projected to reach CNY 239.06 billion, a 5.9% increase from 2023[122]

Investment Rating - The report assigns an "Outperform" rating to the company, indicating an expected relative performance above the market benchmark [17][19]. Core Insights - The company is focusing on self-owned product sales while reducing the proportion of agency business, which has decreased from 50% in 2017 to below 3% in 2022. This strategic shift aims to enhance innovation and research capabilities, with R&D expense ratio increasing from 6.39% in 2018 to 8.3% in 2022 [17][19]. - The company has successfully won multiple bids in national drug procurement, which is expected to significantly boost market share and performance for selected products. The trend of price reductions in centralized procurement is also showing signs of moderation [4][19]. - The innovative drug AR882 for gout treatment shows promising clinical results, with significant reductions in serum uric acid levels and favorable safety profiles, indicating potential for long-term growth in this therapeutic area [5][19]. - The company has implemented multiple equity incentive plans from 2018 to 2022, reflecting confidence in long-term development and aiming to motivate key personnel [6][19]. Financial Overview - The company reported a revenue of 22.80 billion in 2022, with a year-on-year growth of 3.7%. The projected revenues for 2023, 2024, and 2025 are 26.91 billion, 33.72 billion, and 43.29 billion respectively, with expected growth rates of 18.0%, 25.3%, and 28.4% [18][19]. - Net profit for 2022 was 291 million, with projections of 321 million, 403 million, and 510 million for the following years, reflecting growth rates of 10.3%, 25.6%, and 26.7% [18][19]. - The company maintains a stable gross margin around 85%, with slight fluctuations expected in the coming years [18][19]. Business Segments - The pediatric segment is expected to grow at rates of 25.1%, 21.7%, and 23.6% from 2023 to 2025, maintaining a gross margin of approximately 87.5% [21][19]. - The chronic disease segment is projected to experience a decline in 2023 due to some products being removed from insurance coverage, but is expected to recover in 2024 and 2025 with growth rates of 14.2% and 17.8% [21][19]. - The chemical generic drug segment is anticipated to grow significantly, with projected growth rates of 28.9%, 58.1%, and 56.5% from 2023 to 2025, benefiting from successful bids in centralized procurement [21][19].

证券代码：300723 证券简称：一品红 公告编号：2024-008 一品红药业股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、变更事由和程序 一品红药业股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开第 三届董事会第二十一次会议、2024 年 1 月 31 日召开 2024 年第一次临时股东大 会，审议通过了《关于修订<公司章程>的议案》。因"一品转债（债券代码：123098）" 持有人于 2023 年 7 月 7 日至 2023 年 7 月 24 日间持续转股。以及《中华人民共 和国证券法》《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则 （2023 年 8 月修订）》《上市公司章程指引（2023 年修订）》《上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等相关法律法规及规范性文件的最新 修订，为进一步提升公司规范运作水平，完善公司治理结构，公司全面梳理相关 治理制度，通过对照自查，同时结合公司自身实际情况，对《公司章程》及相关 治理制度进行了系统性的梳理，需对公司 ...

北京市中伦（广州）律师事务所（以下简称"本所"）受一品红药业股份有 限公司（以下简称"公司"）委托，指派本所律师刘杰、杨小颖（以下简称"本所 律师"）出席公司 2024 年第一次临时股东大会（以下简称"本次股东大会"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市 公司股东大会规则》等有关法律、法规、规范性文件及《一品红药业股份有限公 司章程》（以下简称"《公司章程》"）的规定，对公司本次股东大会进行见证 并出具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材 料。本所律师得到公司如下保证，即其已提供了本所律师认为作为出具本法律 意见书所必需的材料，所提供的原始材料、副本、复印件等材料、口头证言均 符合真实、准确、完整的要求，有关副本、复印件等材料与原始材料一致。 广东省广州市天河区珠江新城华夏路 10 号富力中心 23 楼整层及 31 楼 01、04 单元 邮编：510623 23/F, Units 01 & 04 of 31/F, R&F Center, 10 Huaxia Road, Zhujiang New Town, Tianhe Distri ...

证券代码：300723 证券简称：一品红 公告编号：2024-007 一品红药业股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决议案的情况； 2、本次股东大会未涉及变更以往股东大会决议的情形； 3、本次股东大会采取现场投票与网络投票表决相结合的方式召开； 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议时间：2024 年 1 月 31 日（星期三）下午 14：30 开始。 （2）网络投票时间：2024 年 1 月 31 日。 ①通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 1 月 31 日交易 日上午 9：15—9：25，9：30-11：30，下午 13：00-15：00。 ②通过深圳证券交易所互联网系统投票的时间为 2024 年 1 月 31 日上午 9:15 至下午 15:00。 2、现场会议召开地点：广州市黄埔区广州国际生物岛寰宇一路 27 号云润大厦 19 层。 3、出席本次股东大会的其他人员为公司的董事、 ...

药品通用名称：苯磺酸氨氯地平干混悬剂 英文名/拉丁名：Amlodipine Besilate for Suspension 主要成份：苯磺酸氨氯地平 证券代码：300723 证券简称：一品红 公告编号：2024-006 一品红药业股份有限公司 关于全资子公司获得苯磺酸氨氯地平干混悬剂注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业股份有限公司（以下简称"公司"）全资子公司广州一品红制药 有限公司于近日收到国家药品监督管理局核准签发的关于苯磺酸氨氯地平干混 悬剂的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 剂 型：干混悬剂 注册分类：化学药品 2.2 类 规 格：15g:100mg（按 C20H25ClN2O5计） 药品注册标准编号：YBH00132024 药品有效期：24 个月 申请事项：药品注册（境内生产） 包装规格： 15g/瓶/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产 ...

一品红药业股份有限公司 独立董事工作制度 第一章 总 则 第一条 为完善公司法人治理结构，促进一品红药业股份有限公司（以下简称 "公司"）规范运作，维护公司整体利益，有效保障全体股东、特别是中小股东的 合法权益不受损害，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司独立董事管 理办法》《深圳证券交易所创业板股票上市规则》（以下简称"《股票上市规则》"） 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称"《创业板上司公司规范运作》"）等有关法律、法规、规范性文件 和《一品红药业股份有限公司公司章程》（以下简称"《公司章程》"）的有关规 定，制定本制度。 第二条 独立董事是指不在本公司担任除董事外的其他职务，并与公司及其主 要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独 立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有诚信与勤勉义务。独立董事应当按照 相关法律法规和公司章程的要求，认真履行职责、维护公司整体利益，尤其要关 注中小股东的合法利益不受损害。独立董事应当独立 ...